Orbimed Advisors LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Orbimed Advisors LLC reported 105 stock positions worth $4.4 billion. Its top holding was Edgewise Therapeutics (EWTX) at 11.1% of the portfolio, followed by Enliven Therapeutics (ELVN, 7.1%) and Eli Lilly (LLY, 4.9%). Compared with Q4 2025, it opened 21 new positions, sold out of 20, added to 24 and reduced 35. The biggest buy was a new position in Astrazeneca (AZN) and the biggest sale an exit from Terns Pharmaceuticals (TERN).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0001055951
- Portfolio Value
- $4.4B (Q1 2026)
- SEC Filing
- 0001172661-26-002369 ↗ filed May 15, 2026
Holdings Value
Holdings 105 stocks · $4.4B
| EWTX Edgewise Therapeutics Inc. | 11.06% | 15,518,492 | $488.8M | No change |
| ELVN Enliven Therapeutics Inc. | 7.06% | 7,959,538 | $312.0M | No change |
| LLY Eli Lilly & Co. | 4.93% | 236,800 | $217.8M | Reduce -21.4% |
| SVA Sinovac Biotech Ltd. | 4.17% | 2,718,735 | $184.5M | No change |
| BSX Boston Scientific Corp. | 3.38% | 2,382,100 | $149.5M | Reduce -1.5% |
| SION Sionna Therapeutics Inc. | 3.20% | 3,530,702 | $141.5M | Reduce -0.9% |
| AZN Astrazeneca PLC | 2.99% | 670,200 | $132.2M | New |
| MBX MBX Biosciences Inc. | 2.46% | 3,637,887 | $108.6M | Reduce -7.6% |
| CRVS Corvus Pharmaceuticals Inc. | 2.37% | 7,165,006 | $104.8M | No change |
| ARGX Argenx SE - ADR | 2.26% | 136,900 | $100.0M | Reduce -6.2% |
| EW Edwards Lifesciences Corp. | 2.23% | 1,230,600 | $98.5M | Reduce -33.2% |
| ISRG Intuitive Surgical Inc. | 2.18% | 208,700 | $96.2M | Reduce -20.8% |
| CMPX Compass Therapeutics Inc. | 1.82% | 15,219,994 | $80.5M | No change |
| MRK Merck & Co. Inc. | 1.81% | 663,400 | $79.8M | New |
| GPCR Structure Therapeutics Inc. | 1.61% | 1,475,403 | $71.1M | Add +27.0% |
| AVBP Arrivent Biopharma Inc. | 1.58% | 3,027,328 | $69.8M | No change |
| IRON Disc Medicine Inc. | 1.54% | 1,067,550 | $68.3M | No change |
| SPRY Ars Pharmaceuticals Inc. | 1.51% | 8,288,510 | $66.6M | No change |
| CGON CG Oncology Inc. | 1.45% | 948,267 | $64.2M | Reduce -37.5% |
| XENE Xenon Pharmaceuticals Inc. | 1.39% | 1,059,971 | $61.6M | Add +137.0% |
| SYK Stryker Corp. | 1.36% | 182,500 | $60.0M | Reduce -43.9% |
| BMY Bristol-Myers Squibb Co. | 1.27% | 925,000 | $56.1M | Add +19.4% |
| MLYS Mineralys Therapeutics Inc. | 1.26% | 2,052,900 | $55.6M | Add +109.4% |
| PRAX Praxis Precision Medicines I | 1.26% | 172,500 | $55.6M | Add +82.5% |
| PFE Pfizer Inc. | 1.24% | 1,946,500 | $54.7M | Add +17.8% |
| DYN Dyne Therapeutics Inc. | 1.20% | 2,917,884 | $52.9M | Add +32.5% |
| NTRA Natera Inc. | 1.19% | 262,000 | $52.4M | Reduce -28.4% |
| ABVX Abivax SA-ADR | 1.17% | 465,700 | $51.9M | Add +26.6% |
| UPB Upstream Bio Inc. | 1.16% | 5,693,589 | $51.2M | No change |
| DHR Danaher Corp. | 1.14% | 265,800 | $50.4M | Reduce -11.3% |
| CAI Caris Life Sciences Inc. | 1.14% | 2,806,811 | $50.2M | Reduce -9.9% |
| ASND Ascendis Pharma A/S | 0.94% | 181,977 | $41.6M | Add +5.8% |
| STTK Shattuck Labs Inc. | 0.92% | 6,306,127 | $40.5M | No change |
| GH Guardant Health Inc. | 0.91% | 435,200 | $40.2M | New |
| ALNY Alnylam Pharmaceuticals Inc. | 0.89% | 119,000 | $39.4M | Reduce -58.8% |
| PRLD Prelude Therapeutics Inc. | 0.84% | 10,909,256 | $37.3M | No change |
| CRNX Crinetics Pharmaceuticals Inc. | 0.82% | 999,000 | $36.3M | No change |
| AXSM Axsome Therapeutics Inc. | 0.82% | 213,921 | $36.2M | Reduce -15.5% |
| QURE Uniqure NV | 0.79% | 2,136,149 | $34.9M | Add +189.7% |
| ORIC Oric Pharmaceuticals Inc. | 0.77% | 2,693,929 | $34.1M | Reduce -26.0% |
| ELV Elevance Health Inc. | 0.76% | 114,700 | $33.6M | Add +15.7% |
| RLMD Relmada Therapeutics Inc. | 0.74% | 4,715,864 | $32.8M | Add +80.6% |
| FBRX Forte Biosciences Inc. | 0.70% | 1,196,955 | $31.0M | No change |
| TRVI Trevi Therapeutics Inc. | 0.66% | 2,454,400 | $29.3M | Reduce -23.1% |
| ESPR Esperion Therapeutics Inc. | 0.66% | 10,570,300 | $29.0M | Add +77.2% |
| NPCE Neuropace Inc. | 0.62% | 2,096,527 | $27.6M | Reduce -12.9% |
| RYTM Rhythm Pharmaceuticals Inc. | 0.62% | 314,100 | $27.3M | Add +31.0% |
| TMO Thermo Fisher Scientific Inc. | 0.52% | 46,500 | $22.9M | No change |
| SNDX Syndax Pharmaceuticals Inc. | 0.51% | 962,300 | $22.5M | New |
| 0 | 0.50% | 6,210,899 | $22.1M | No change |
| BTSG Brightspring Health Services | 0.48% | 497,800 | $21.2M | Add +1.9% |
| LXEO Lexeo Therapeutics Inc. | 0.47% | 3,602,450 | $20.7M | Add +69.5% |
| STRO Sutro Biopharma Inc. | 0.45% | 801,144 | $20.0M | New |
| NKTR Nektar Therapeutics | 0.45% | 275,000 | $19.8M | New |
| HELP Cybin Inc. | 0.42% | 3,832,843 | $18.4M | Reduce -0.2% |
| KRYS Krystal Biotech Inc. | 0.40% | 69,100 | $17.8M | Reduce -42.3% |
| PVLA Palvella Therapeutics Inc. | 0.38% | 134,600 | $16.8M | New |
| CRBP Corbus Pharmaceuticals Holdi | 0.37% | 1,737,287 | $16.3M | Add +8.8% |
| URGN Urogen Pharma Ltd. | 0.36% | 875,487 | $15.7M | No change |
| DFTX Definium Therapeutics Inc. | 0.34% | 804,000 | $15.2M | Reduce -34.5% |
| VERA Vera Therapeutics Inc. | 0.34% | 369,596 | $14.9M | Add +4.5% |
| QTTB Q32 Bio Inc. | 0.33% | 2,252,987 | $14.5M | No change |
| WHWK Whitehawk Therapeutics Inc. | 0.33% | 4,166,000 | $14.4M | No change |
| AMGN Amgen Inc. | 0.32% | 39,900 | $14.0M | New |
| ALHC Alignment Healthcare Inc. | 0.32% | 791,000 | $13.9M | New |
| EYPT Eyepoint Inc. | 0.31% | 1,069,147 | $13.8M | Reduce -56.7% |
| JANX Janux Therapeutics Inc. | 0.31% | 983,600 | $13.7M | Reduce -49.7% |
| BCRX Biocryst Pharmaceuticals Inc. | 0.31% | 1,425,200 | $13.6M | Reduce -18.2% |
| BCAX Bicara Therapeutics Inc. | 0.30% | 667,300 | $13.3M | Add +219.1% |
| BIOA Bioage Labs Inc. | 0.28% | 711,811 | $12.4M | Reduce -10.0% |
| COGT Cogent Biosciences Inc. | 0.28% | 322,100 | $12.4M | Reduce -13.2% |
| ALMS Alumis Inc. | 0.27% | 548,163 | $12.1M | Reduce -50.3% |
| REGN Regeneron Pharmaceuticals | 0.26% | 14,700 | $11.4M | New |
| CARL Carlsmed Inc. | 0.26% | 1,252,600 | $11.3M | No change |
| BIIB Biogen Inc. | 0.26% | 61,600 | $11.3M | New |
| KNSA Kiniksa Pharmaceuticals Inte | 0.20% | 180,599 | $8.7M | Reduce -3.5% |
| KROS Keros Therapeutics Inc. | 0.19% | 759,155 | $8.4M | Reduce -5.6% |
| GILD Gilead Sciences Inc. | 0.19% | 59,600 | $8.3M | New |
| HRTX Heron Therapeutics Inc. | 0.18% | 9,816,940 | $7.9M | New |
| AVTX Avalo Therapeutics Inc. | 0.16% | 475,165 | $7.1M | Reduce -60.0% |
| TECX Tectonic Therapeutic Inc. | 0.16% | 226,600 | $7.0M | Reduce -60.6% |
| ACET Adicet Bio Inc. | 0.16% | 1,027,944 | $7.0M | No change |
| CMPS Compass Pathways PLC | 0.14% | 1,150,646 | $6.4M | New |
| PHVS Pharvaris NV | 0.13% | 205,400 | $5.8M | No change |
| ALXO Alx Oncology Holdings Inc. | 0.13% | 2,866,256 | $5.7M | New |
| AORT Artivion Inc. | 0.13% | 151,000 | $5.5M | New |
| NSPR Inspiremd Inc. | 0.12% | 3,133,405 | $5.1M | No change |
| RVMD Revolution Medicines Inc. | 0.11% | 52,000 | $5.1M | Add +100.8% |
| ADCT Adc Therapeutics SA | 0.11% | 1,318,026 | $4.9M | Reduce -77.4% |
| PTGX Protagonist Therapeutics Inc. | 0.10% | 42,100 | $4.4M | Add +94.0% |
| PALI Palisade Bio Inc. | 0.09% | 2,333,000 | $4.1M | Add +24.7% |
| ANRO Alto Neuroscience Inc. | 0.09% | 167,500 | $3.8M | Add +34.0% |
| SVRA Savara Inc. | 0.08% | 635,000 | $3.5M | New |
| CGEM Cullinan Therapeutics Inc. | 0.08% | 243,006 | $3.5M | Reduce -10.0% |
| PTCT PTC Therapeutics Inc. | 0.08% | 49,100 | $3.3M | Add +111.6% |
| LFST Lifestance Health Group Inc. | 0.07% | 500,000 | $3.2M | New |
| DRUG Bright Minds Biosciences Inc. | 0.07% | 40,000 | $2.9M | New |
| JBIO Jade Biosciences Inc. | 0.06% | 185,011 | $2.6M | Reduce -65.2% |
| CCCC C4 Therapeutics Inc. | 0.05% | 856,353 | $2.3M | Reduce -39.0% |
| RCEL Avita Medical Inc. | 0.05% | 544,895 | $2.0M | New |
| KALV Kalvista Pharmaceuticals Inc. | 0.04% | 94,400 | $1.9M | Reduce -75.3% |
| IMA Imagenebio Inc. | 0.04% | 378,556 | $1.9M | No change |
| VTGN Vistagen Therapeutics Inc. | 0.04% | 3,060,000 | $1.7M | No change |
| ATAI Ataibeckley Inc. | 0.03% | 347,000 | $1.2M | New |
| TRAW Traws Pharma Inc. | 0.03% | 605,531 | $1.1M | No change |
Options reported separately and not counted above: MDXH calls ($285.9M), RCEL calls ($154.4M), QGEN calls ($10.0M), PVLA calls ($6.2M), SLNO calls ($3.3M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $164.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| MYGN Myriad Genetics Inc. | COM · principal | 125,000,000 | $122.9M | New |
| RCEL Avita Medical Inc. | COM · principal | 40,500,000 | $40.5M | New |
| COGENT BIOSCIENCES INC (COGT 1.625 11/15/31) | NOTE 1.625%11/1 · principal | 1,000,000 | $1.2M | No change |
Total filed on the 13F, all lines: $4.6B.
Portfolio Sells Q4 2025 → Q1 2026
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −1.78 |
| LLY Eli Lilly & Co. | Reduce -21.4% | 4.93% | −1.70 |
| ALNY Alnylam Pharmaceuticals Inc. | Reduce -58.8% | 0.89% | −1.46 |
| BSX Boston Scientific Corp. | Reduce -1.5% | 3.38% | −1.34 |
| APLS Apellis Pharmaceuticals Inc. | Sold out | 0.00% | −1.25 |
| CI The Cigna Group | Sold out | 0.00% | −1.15 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −1.14 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −1.05 |
| EW Edwards Lifesciences Corp. | Reduce -33.2% | 2.23% | −0.99 |
| SYK Stryker Corp. | Reduce -43.9% | 1.36% | −0.98 |
| ROIV Roivant Sciences Ltd. | Sold out | 0.00% | −0.97 |
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −0.91 |
| NBIX Neurocrine Biosciences Inc. | Sold out | 0.00% | −0.91 |
| ISRG Intuitive Surgical Inc. | Reduce -20.8% | 2.18% | −0.88 |
| EXAS Exact Sciences Corp. | Sold out | 0.00% | −0.73 |
| EYPT Eyepoint Inc. | Reduce -56.7% | 0.31% | −0.61 |
| CAI Caris Life Sciences Inc. | Reduce -9.9% | 1.14% | −0.59 |
| BRKR Bruker Corp. | Sold out | 0.00% | −0.54 |
| NTRA Natera Inc. | Reduce -28.4% | 1.19% | −0.53 |
| ADCT Adc Therapeutics SA | Reduce -77.4% | 0.11% | −0.31 |
| CTMX Cytomx Therapeutics Inc. | Sold out | 0.00% | −0.31 |
| VIR Vir Biotechnology Inc. | Sold out | 0.00% | −0.29 |
| AVTX Avalo Therapeutics Inc. | Reduce -60.0% | 0.16% | −0.28 |
| DHR Danaher Corp. | Reduce -11.3% | 1.14% | −0.26 |
| TARS Tarsus Pharmaceuticals Inc. | Sold out | 0.00% | −0.26 |
| ARGX Argenx SE - ADR | Reduce -6.2% | 2.26% | −0.25 |
| JANX Janux Therapeutics Inc. | Reduce -49.7% | 0.31% | −0.24 |
| HELP Cybin Inc. | Reduce -0.2% | 0.42% | −0.23 |
| FOLD Amicus Therapeutics Inc. | Sold out | 0.00% | −0.21 |
| KRYS Krystal Biotech Inc. | Reduce -42.3% | 0.40% | −0.20 |
| RPTX Repare Therapeutics Inc. | Sold out | 0.00% | −0.18 |
| CELC Celcuity Inc. | Sold out | 0.00% | −0.17 |
| TRVI Trevi Therapeutics Inc. | Reduce -23.1% | 0.66% | −0.16 |
| KROS Keros Therapeutics Inc. | Reduce -5.6% | 0.19% | −0.15 |
| NPCE Neuropace Inc. | Reduce -12.9% | 0.62% | −0.14 |
| AXSM Axsome Therapeutics Inc. | Reduce -15.5% | 0.82% | −0.13 |
| PMVP PMV Pharmaceuticals Inc. | Sold out | 0.00% | −0.13 |
| JBIO Jade Biosciences Inc. | Reduce -65.2% | 0.06% | −0.11 |
| INSM Insmed Inc. | Sold out | 0.00% | −0.09 |
| TECX Tectonic Therapeutic Inc. | Reduce -60.6% | 0.16% | −0.09 |
| MBX MBX Biosciences Inc. | Reduce -7.6% | 2.46% | −0.08 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -75.3% | 0.04% | −0.08 |
| OCUL Ocular Therapeutix Inc. | Sold out | 0.00% | −0.04 |
| MPLT Maplight Therapeutics Inc. | Sold out | 0.00% | −0.02 |
| CCCC C4 Therapeutics Inc. | Reduce -39.0% | 0.05% | −0.00 |
| DFTX Definium Therapeutics Inc. | Reduce -34.5% | 0.34% | +0.01 |
| COGT Cogent Biosciences Inc. | Reduce -13.2% | 0.28% | +0.01 |
| CGEM Cullinan Therapeutics Inc. | Reduce -10.0% | 0.08% | +0.02 |
| BCRX Biocryst Pharmaceuticals Inc. | Reduce -18.2% | 0.31% | +0.03 |
| KNSA Kiniksa Pharmaceuticals Inte | Reduce -3.5% | 0.20% | +0.04 |
Portfolio Buys Q4 2025 → Q1 2026
| AZN Astrazeneca PLC | New | 2.99% | +2.99 |
| MRK Merck & Co. Inc. | New | 1.81% | +1.81 |
| XENE Xenon Pharmaceuticals Inc. | Add +137.0% | 1.39% | +0.98 |
| GH Guardant Health Inc. | New | 0.91% | +0.91 |
| PRAX Praxis Precision Medicines I | Add +82.5% | 1.26% | +0.69 |
| MLYS Mineralys Therapeutics Inc. | Add +109.4% | 1.26% | +0.53 |
| SNDX Syndax Pharmaceuticals Inc. | New | 0.51% | +0.51 |
| RLMD Relmada Therapeutics Inc. | Add +80.6% | 0.74% | +0.48 |
| STRO Sutro Biopharma Inc. | New | 0.45% | +0.45 |
| NKTR Nektar Therapeutics | New | 0.45% | +0.45 |
| QURE Uniqure NV | Add +189.7% | 0.79% | +0.43 |
| BMY Bristol-Myers Squibb Co. | Add +19.4% | 1.27% | +0.41 |
| PFE Pfizer Inc. | Add +17.8% | 1.24% | +0.39 |
| PVLA Palvella Therapeutics Inc. | New | 0.38% | +0.38 |
| AMGN Amgen Inc. | New | 0.32% | +0.32 |
| ALHC Alignment Healthcare Inc. | New | 0.32% | +0.32 |
| DYN Dyne Therapeutics Inc. | Add +32.5% | 1.20% | +0.31 |
| REGN Regeneron Pharmaceuticals | New | 0.26% | +0.26 |
| BIIB Biogen Inc. | New | 0.26% | +0.26 |
| BCAX Bicara Therapeutics Inc. | Add +219.1% | 0.30% | +0.23 |
| ESPR Esperion Therapeutics Inc. | Add +77.2% | 0.66% | +0.20 |
| ASND Ascendis Pharma A/S | Add +5.8% | 0.94% | +0.19 |
| GILD Gilead Sciences Inc. | New | 0.19% | +0.19 |
| HRTX Heron Therapeutics Inc. | New | 0.18% | +0.18 |
| ABVX Abivax SA-ADR | Add +26.6% | 1.17% | +0.16 |
| CMPS Compass Pathways PLC | New | 0.14% | +0.14 |
| ALXO Alx Oncology Holdings Inc. | New | 0.13% | +0.13 |
| AORT Artivion Inc. | New | 0.13% | +0.13 |
| BTSG Brightspring Health Services | Add +1.9% | 0.48% | +0.11 |
| CRBP Corbus Pharmaceuticals Holdi | Add +8.8% | 0.37% | +0.10 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +31.0% | 0.62% | +0.09 |
| SVRA Savara Inc. | New | 0.08% | +0.08 |
| RVMD Revolution Medicines Inc. | Add +100.8% | 0.11% | +0.07 |
| LFST Lifestance Health Group Inc. | New | 0.07% | +0.07 |
| DRUG Bright Minds Biosciences Inc. | New | 0.07% | +0.07 |
| PTGX Protagonist Therapeutics Inc. | Add +94.0% | 0.10% | +0.06 |
| ELV Elevance Health Inc. | Add +15.7% | 0.76% | +0.05 |
| RCEL Avita Medical Inc. | New | 0.05% | +0.05 |
| ANRO Alto Neuroscience Inc. | Add +34.0% | 0.09% | +0.04 |
| PTCT PTC Therapeutics Inc. | Add +111.6% | 0.08% | +0.04 |
| LXEO Lexeo Therapeutics Inc. | Add +69.5% | 0.47% | +0.04 |
| ATAI Ataibeckley Inc. | New | 0.03% | +0.03 |
| PALI Palisade Bio Inc. | Add +24.7% | 0.09% | +0.00 |
| VERA Vera Therapeutics Inc. | Add +4.5% | 0.34% | −0.03 |
| GPCR Structure Therapeutics Inc. | Add +27.0% | 1.61% | −0.05 |
Options Activity Q4 2025 → Q1 2026
| MDXH Mdxhealth | call | New | 124,306,000 | $285.9M |
| RCEL Avita Medical Inc. | call | New | 40,966,100 | $154.4M |
| EW Edwards Lifesciences Corp. | call | Sold out | 150,000 | $12.8Mbefore exit |
| QGEN Qiagen N.V. | call | New | 250,000 | $10.0M |
| PVLA Palvella Therapeutics Inc. | call | New | 50,000 | $6.2M |
| SLNO Soleno Therapeutics Inc. | call | New | 100,000 | $3.3M |
| VTGN Vistagen Therapeutics Inc. | call | Sold out | 45,200 | $30Kbefore exit |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2025 → Q1 2026
| MYGN Myriad Genetics Inc. | COM · principal | New | 125,000,000 | $122.9M |
| RCEL Avita Medical Inc. | COM · principal | New | 40,500,000 | $40.5M |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 117 | $5.3B | EWTX, ELVN, LLY, MBX, SVA |
| Q1 2026 | 105 | $4.4B | EWTX, ELVN, LLY, SVA, BSX |
| Q4 2025 | 104 | $4.9B | EWTX, LLY, BSX, SVA, EW |
| Q3 2025 | 98 | $4.2B | EWTX, BSX, LLY, SVA, ELVN |
| Q2 2025 | 97 | $4.0B | SVA, BSX, LLY, EWTX, ELVN |
| Q1 2025 | 106 | $4.2B | SVA, EWTX, BSX, LLY, ELVN |
| Q4 2024 | 111 | $4.8B | EWTX, SVA, BSX, LLY, ISRG |
| Q3 2024 | 109 | $5.5B | EWTX, SVA, LLY, BSX, ISRG |
| Q2 2024 | 108 | $5.0B | SVA, LLY, EWTX, BSX, ISRG |
| Q1 2024 | 112 | $5.4B | SVA, LLY, EWTX, BSX, ISRG |